Strides receives tentative approval for Efavirenz
27 May 2016 | News | By BioSpectrum Bureau
Strides receives tentative approval for Efavirenz
(Photo Courtesy: www.myvisiontrack.com)
Efavirenz is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults and adolescents.
The final approval will be received after Patent Expiry in August 2018.
According to IMS data, the US market for Efavirenz 600 mg Tablet is approximately USD $150 million.
The product will be manufactured at the company's oral dosage facility in Bangalore, and marketed by Strides in the US market.
